Dr. Thomas G. Mahrer MD

Recommended Articles

• Is There a Link Between Asthma and Bronchitis?

  Bronchitis and Asthma are both inflammatory conditions that affect lungs where a person’s airways swell up, causing them breathing problems.Asthma, also known as bronchial asthma, is characterized as a chronic condition in which a person’s airways become inflamed, narrow and swollen, and produce...

• The Link Between Playing Musical Instruments and Cystic Fibrosis

  Vincent Forknor is an 8-year-old boy from Ramsey, Cambridge in the United Kingdom who has Cystic Fibrosis (CF). He has recently started playing the bagpipes, and his family has noticed an improvement in his CF symptoms since he began this new hobby. Vincent takes common CF medications and undergoes...

• How Is Bronchitis Differentiated from Other Chest Infections?

  Bronchial tubes are the airways through which air travels and reaches the lungs. The inflammation of these bronchial tubes is called bronchitis. The inflammation is more often caused by a viral infection, smoke, dust, or other irritants.Bronchitis may be due to a chest infection, inflammation of...

• New Study May Explain Mucus Issues in People with CF

  As someone with cystic fibrosis, you probably sometimes have difficulty breathing. You may even know that the cause of the trouble most often relates to the mucus in your lungs. It is a clear, green or yellow slime which causes intense aggravation. In the case of people with cystic fibrosis, it can...

• What This New Therapeutic Drug Trial Means for Cystic Fibrosis

  If you have cystic fibrosis, chances are that at some point you have had difficulty breathing due to mucus build-up in your lungs. That thick mucus can make it more than just hard to breathe, as it can cause inflammation and increase your chance of injury. Clear airways may be just around the corner...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...